GSK PLC (LSE:GSK, NYSE:GSK) has announced positive results from the phase III trial of its MenABCWY combination vaccine candidate in meningococcal, a major cause of meningitis and septicaemia.
The drug, a five-in-one amalgam of treatments, was administered in two doses given six months apart.
It was tested for its safety, tolerability and immunogenicity (its ability to vaccinate) in healthy people aged between 10 and 25 years.
The evaluation had 11 separate goals, or endpoints, and achieved all of them.
As MenABCWY is a broad-based meningococcal vaccine it is hoped it will provide the widest possible protection against the disease.
"These statistically significant phase III data are a very encouraging step toward reducing the incidence of meningococcal disease,” said GSK’s chief medical officer, Tony Wood in a statement.
“In the US, routine use of a 5-in-1 meningococcal vaccine with a two-dose regimen in adolescents at 16 to 18 years of age, just before this disease's incidence peak, could drive significant public health impact.
“In addition, our 5-in-1 meningococcal vaccine candidate builds on our global leadership in meningococcal vaccines and commitment to innovation," he added.